Sorafenib, a small molecule multikinase inhibitor, is the standard of care in the USA and Europe for the treatment of advanced hepatocellular carcinoma. This article reviews its development from the basis of molecular hepatocarcinogenesis to phase III trials and discusses the future for sorafenib in hepatocellular carcinoma.
PDF的下载单位、IP信息已删除
(2025-6-4)
秋风
无极微光
aajhajkahna
aaaKumaINmyMIND
健健康康的生活
DW
学霸业
YY
GingerF
林狗
aaaa
wangyumumu
寒2026
学术文献互助
Dean
科研狗
Nole
认真的不评
xiaolizi
共产主义战士
皖公网安备34019202002308
